New drug promising in prostate cancer
A new androgen receptor inhibitor, apalutamide, has shown promising results in a phase 3 trial published in the New England Journal of Medicine (doi: 10.1056/NEJMoa1715546).
Researchers investigated the efficacy of apalutamide in 1207 men with non-metastatic castration-resistant prostate cancer and a PSA doubling time of 10 months or less who were at high risk of metastasis.
Median metastasis-free survival was 40.5 months in the apalutamide group compared to 16.2 months in the placebo group (hazard ratio [HR] 0.28; 95% CI 0.23–0.35; p<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (HR 0.45; 95% CI 0.32–0.63; p<0.001). The rate of adverse events leading to discontinuation was 10.6% in the apalutamide group and 7% in the placebo group.